A healthcare provider may prescribe Tasigna® (nilotinib) to help treat a certain type of cancer called chronic myeloid leukemia (CML). It is only approved for use in people age 18 and older.
CML is a slowly progressing leukemia in which bone marrow stem cells (the early cells that form blood cells) develop into many abnormal granulocytes (a type of white blood cell). Some of these cells never become mature white blood cells (also called blasts). Over time, the granulocytes and blasts crowd out the red blood cells and platelets in the bone marrow.
As a chemotherapy drug, Tasigna works to treat CML by reducing the activity of a certain type of protein in the body that the cancer cells need to grow and multiply.
(For more details on this chemotherapy drug, click Tasigna. This Web selection explores this medicine in detail, including possible side effects, dosing guidelines, and safety precautions.)